ArticleCardiovascular and interventional radiology2020
Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma.
Article in Cardiovascular and interventional radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- The use of computed tomography during follow-up after ablation of cT1 renal cell carcinoma: evidence for overuse.European radiology · 2026Pooled it
- Perioperative, functional and oncologic outcomes of percutaneous ablation versus minimally invasive partial nephrectomy for clinical T1 renal tumors: outcomes from a pooled analysis.Journal of robotic surgery · 2024Pooled it
- Clinical Study on the Efficacy of Microwave Ablation (MA) in the Treatment of Stage I Renal Clear Cell Carcinoma by CT and MRI Imaging.Journal of healthcare engineering · 2022Trial
- Advances in the Role of Chemokines in Microwave Ablation-Based Combinatorial Immunotherapy.Cancer science · 2026Review
- Percutaneous thermal ablation for renal cell carcinoma: a comprehensive review of current evidence and future directions.La Radiologia medica · 2026Review
- Percutaneous ablation of T1b renal tumors: a review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Renal Arteriography and C-arm CT-Guided Ablation (RenACAGA) for Thermal Ablation of Challenging Renal Tumors.Cardiovascular and interventional radiology · 2025Article
- Percutaneous Microwave Ablation versus Cryoablation for Small Renal Masses (≤4 cm): 12-Year Experience at a Single Center.Journal of vascular and interventional radiology : JVIR · 2024Article
- Computed tomography-guided percutaneous microwave ablation for renal cell carcinoma: evaluating the performance of nephrometry scores.European radiology · 2023Article
- Review
- Generic surgical process model for minimally invasive liver treatment methods.Scientific reports · 2022Article
- Applied Change Management in Interventional Radiology-Implementation of Percutaneous Thermal Ablation as an Additional Therapeutic Method for Small Renal Masses.Diagnostics (Basel, Switzerland) · 2022Article
- Computed Tomography-Guided Percutaneous Microwave Ablation for Renal Cell Carcinoma: Impact of Tumor Size on the Progression Survival Rates.Diagnostics (Basel, Switzerland) · 2021Article
- Combined Angio-CT Systems: A Roadmap Tool for Precision Therapy in Interventional Oncology.Radiology. Imaging cancer · 2021Review
- Long-term outcomes of CT-guided percutaneous cryoablation of T1a and T1b renal cell carcinoma.Diagnostic and interventional radiology (Ankara, Turkey) · 2021Article
- Outcomes of Microwave Ablation for Small Renal Masses: A Single Center Experience.Journal of endourology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the safety and efficacy of percutaneous microwave ablation (MWA) of histologically proven T1 renal cell carcinoma (RCC).
methodsWe analysed patients with a histologically proven RCC (≤ 7 cm) treated by MWA from April 2012-April 2018. Primary and secondary efficacy, local tumour recurrence (LTR), morbidity and mortality were reported. Efficacy was defined as no residual tumour enhancement on follow-up imaging 1 month after the first ablation (primary efficacy) and after re-ablation(s) for residual disease (secondary efficacy). Adverse events (AE) were registered by the Clavien-Dindo classification and the common terminology criteria for AE. Univariable and multivariable logistic regression analyses were performed to investigate a relation among pre-treatment factors incomplete ablation and complications.
resultsIn 100 patients, a total of 108 RCCs (85 T1a and 23 T1b) were treated by MWA. Median size was 3.2 cm (IQR 2.4-4.0). Primary efficacy was 89% (95%CI 0.81-0.94) for T1a lesions and 52% (95%CI 0.31-0.73) for T1b lesions (p < 0.001). Fifteen lesions (7 T1a) were re-ablated for residual disease by MWA in one (n = 13) and two (n = 2, both T1b) sessions resulting in secondary efficacy rates of 99% (T1a) and 95% (T1b, p = 0.352). LTR occurred in four tumours (2 T1a, 2 T1b) after 10-60 months. Six (4%) AEs grade > 3-5 were observed (2 T1a, 4 T1b, p = 0.045). Multivariable analysis showed that mR.E.N.A.L. nephrometry was independently associated with incomplete ablation (p = 0.012).
conclusionMicrowave ablation is safe and effective for T1a and T1b RCC lesions with a significantly lower primary efficacy for T1b lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.